A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Proof-of-concept Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Overactive Bladder (OAB) Over a 12-week Treatment Period
Latest Information Update: 02 Feb 2024
At a glance
- Drugs Eliapixant (Primary)
- Indications Overactive bladder
- Focus Proof of concept; Therapeutic Use
- Acronyms 19733 OVADER BAY1817080; OVADER
- Sponsors Bayer
Most Recent Events
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 08 Feb 2022 This trial has been completed in Sweden (End Date: 21 Jan 2022), according to European Clinical Trials Database record.
- 02 Feb 2022 This trial has been completed in Poland (End Date: 21 Jan 2022), according to European Clinical Trials Database record.